Ad hoc data from KEYNOTE-905/EV-303 showed consistent efficacy contributions for both enfortumab vedotin and pembrolizumab in cisplatin-ineligible MIBC #blcsm #oncology

OncLive.com· @OncLive · X·2026-10-24 05:13· 2 天前评分70

正文 · 机器翻译

KEYNOTE-905/EV-303 的临时数据显示，在不适合接受顺铂的 MIBC 中，enfortumab vedotin 和 pembrolizumab 均对疗效有稳定贡献 #blcsm #oncology

阅读更多来自 @myESMO #ESMO26 的内容：https://www.onclive.com/view/ad-hoc-analysis-supports-contributions-of-both-enfortumab-vedotin-and-pembrolizumab-in-cisplatin-ineligible-mibc

251 浏览 · 0 赞 · 0 转发 · 0 回复

会议摘要

4733O按 Proffered paper 1: Genitourinary tumour, renal and urothelial 对上

Perioperative pembrolizumab (pembro) or enfortumab vedotin (EV) plus pembro in pts with muscle-invasive bladder cancer (MIBC) who are cisplatin-ineligible: ad hoc analysis from KEYNOTE-905

https://esmocongress.esmo.org

NCT03924895NCT03924895按 - **标题 / Title：** Perioperative Pembrolizumab (MK-3475) Plus Cystectomy or Perioperative Pembrolizumab Plus Enfortumab Vedotin Plus Cystectomy Versus Cystectomy Alone in Participants Who Are Cisplatin-ineligible or Decline Cisplatin With Muscle-invasive Bladder Cancer (MK-3475-905/KEYNOTE-905/EV-303) 对上

- **标题 / Title：** Perioperative Pembrolizumab (MK-3475) Plus Cystectomy or Perioperative Pembrolizumab Plus Enfortumab Vedotin Plus Cystectomy Versus Cystectomy Alone in Participants Who Are Cisplatin-ineligible or Decline Cisplatin With Muscle-invasive Bladder Cancer (MK-3475-905/KEYNOTE-905/EV-303)

https://esmocongress.esmo.org

来源：OncLive.com · x.com